Skip to main content

Table 2 Statistical evaluation of nuclear and cytosol staining between different time points

From: Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy

A Pre EE2 (n=10) mean (S.E.) During + Post EE2 (n=8) mean (S.E.) P-value B Pre EE2 (n=10) mean (S.E.) During EE2 (n=3) mean (S.E.) Post EE2 (N=5) mean (S.E.) P-value
ER nuc 166.7 (9.0) 68.3 (18.2) 0.0006** ER nuc 166.7 (9.0) 68.0 (28.8) 68.6 (26.1) 0.0024**
PgR nuc 19.2 (15.8) 113.1 (24.1) 0.01* PgR nuc 19.2 (15.8) 171.3 (17.9) 78.2 (26.8) 0.0113*
Ki67 nuc 12.3 (1.96) 22.5 (5.82) 0.2 Ki67 nuc 12.3 (1.96) 10.0 (5.0) 30.0 (7.07) 0.052
BRCA1 nuc 96.6 (5.79) 64.8 (16.7) 0.3 BRCA1 nuc 96.6 (5.79) 57.3 (34.3) 69.4 (20.3) 0.56
cyto 0 (0) 36.6 (17.8) 0,047* cyto 0 (0) 0 (0) 58.6 (23.9) 0.0126*
AR nuc 119.2 (9.79) 44.2 (17.2) 0.039* AR nuc 119.2 (.979) 75.3 (28.7) 25.6 (18.7) 0.0065**
cyto 14.0 (9.79) 68.75 (15.7) 0.0097** cyto 14.0 (9.79) 98.0 (1.52) 51.2 (22.0) 0.0092**
PI3K cyto 83.3 (9.39) 95.0 (5.73) 0.31 PI3K cyto 83.3 (9.3) 98.3 (1.66) 93.0 (9.41) 0.53
AKT nuc 44.3 (11.3) 37.2 (12.6) 0.72 AKT nuc 44.3 (11.3) 35.6 (25.0) 38.2 (16.0) 0.9
cyto 75.2 (9.69) 76.8 (11.8) 0.58   cyto 75.2 (9.69) 83.3 (12.0) 73.0 (18.3) 0.81
pAKT nuc 7.2 (4.5) 17.2 (16.5) 0.63 pAKT nuc 7.2 (4.5) 0 (0) 27.6 (26.3) 0.44
cyto 25.9 (11.4) 23.1 (15.1) 0.57 cyto 25.9 (11.4) 0 (0) 37.0 (22.6) 0.36
IGT1Rb cyto 52.5 (13.3) 32.5 (16.1) 0.37 IGT1Rb cyto 52.5 (13.3) 30.0 (30.0) 34.0 (21.4) 0.64
TUNEL 5.1 (2.42) 3.0 (1.26) 0.74 TUNEL 5.1 (2.44) 2.0 (2.0) 3.6 (1.74) 0.75
  1. The Wilcoxon test/the Kruskal-Wallis test was used to analyze the significance of differences between groups.
  2. nuc: nuclear, cyto: cytosol.
  3. *<0.05, **<0.01.